Nuvalent Inc
NUVL77.100USD
-0.660-0.85%
交易中 （美東）報價延遲15分鐘
5.53B總市值
虧損本益比TTM
關於 Nuvalent Inc 公司
Nuvalent, Inc. 是一家臨牀階段的生物製藥公司，專注於爲臨牀驗證的癌症激酶靶點開發精準靶向療法。該公司開發的小分子具有克服耐藥性、最大程度減少不良事件、解決腦轉移和推動更持久反應的潛力。該公司正在推進強大的產品線，其中包括針對 ROS1 陽性、ALK 陽性和 HER2 陽性非小細胞肺癌的在研候選藥物以及多個發現階段的研究項目。其候選產品 NVL-520 正在爲 ROS 原癌基因 1 (ROS1) 陽性非小細胞肺癌 (NSCLC) 患者開發。NVL-520 是一種新型 ROS1 選擇性抑制劑。其候選產品 NVL-655 正在爲間變性淋巴瘤激酶 (ALK) 陽性 NSCLC 患者開發。LC。NVL-655 是一種腦滲透性 ALK 選擇性抑制劑。其候選產品 NVL-330 是一種腦滲透性人表皮生長因子受體 2 (HER2) 選擇性抑制劑。
公司簡介
公司代碼NUVL
公司名稱Nuvalent Inc
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
員工數量142
證券類型Ordinary Share
年結日Jul 29
公司地址One Broadway, 14Th Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話18573577000
網址https://www.nuvalent.com/
公司代碼NUVL
上市日期Jul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
股東類型
持股股東
佔比
Hedge Fund
48.82%
Investment Advisor
35.80%
Investment Advisor/Hedge Fund
19.30%
Individual Investor
2.87%
Private Equity
2.46%
Research Firm
1.99%
Venture Capital
0.77%
Sovereign Wealth Fund
0.48%
Pension Fund
0.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
438
74.96M
112.94%
-1.46M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
2023Q1
202
57.17M
111.42%
-2.69M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deerfield Management Company, L.P.
17.99M
27.11%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
9.70M
14.61%
+99.92K
+1.04%
Mar 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.94%
-93.95K
-1.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
6.68%
-60.03K
-1.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
4.11%
-65.91K
-2.36%
Mar 31, 2025
Commodore Capital LP
1.85M
2.79%
+233.40K
+14.39%
Mar 31, 2025
Shair (Matthew)
1.64M
2.48%
+2.65K
+0.16%
Jun 18, 2025
Perceptive Advisors LLC
1.63M
2.46%
-986.01K
-37.63%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
1.45M
2.18%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.44M
2.17%
+157.81K
+12.28%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Tema Oncology ETF
3.99%
ALPS Medical Breakthroughs ETF
3.42%
Global X Guru Index ETF
1.27%
SPDR S&P Biotech ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
ProShares Ultra Nasdaq Biotechnology
0.56%
Invesco Nasdaq Biotechnology ETF
0.56%
iShares Health Innovation Active ETF
0.54%
Direxion Daily S&P Biotech Bull 3X Shares
0.53%
iShares Biotechnology ETF
0.35%
查看更多
Tema Oncology ETF
佔比3.99%
ALPS Medical Breakthroughs ETF
佔比3.42%
Global X Guru Index ETF
佔比1.27%
SPDR S&P Biotech ETF
佔比0.93%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.88%
ProShares Ultra Nasdaq Biotechnology
佔比0.56%
Invesco Nasdaq Biotechnology ETF
佔比0.56%
iShares Health Innovation Active ETF
佔比0.54%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.53%
iShares Biotechnology ETF
佔比0.35%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
